Dana Farber Cancer Institute: $3.4B Revenue, $3.0B Expenses

On the NonprofitTruth efficiency rubric, Dana Farber Cancer Institute pulls an A — the highest available grade. The 85/100 composite reflects strong financial reserves, controlled officer compensation, and the kind of multi-year financial discipline that grant-makers look for.

Dana Farber Cancer Institute operates at corporate scale — $3.4B in reported 2023 revenue. At over a billion in annual revenue, nonprofits typically run consolidated operations across multiple states or business lines, and the IRS Form 990 reflects a much larger operational footprint than a typical 501(c)(3). On the reserves factor, Dana Farber Cancer Institute scores well — assets relative to annual spending sit in the range nonprofit-finance experts consider healthy (roughly three months to two years of operating expenses).

Five-year revenue trajectory is strongly positive: Dana Farber Cancer Institute has grown materially in real terms, which usually signals successful fundraising and program expansion. Officer compensation is modest relative to organizational size: Dana Farber Cancer Institute reports $9.8M in total compensation for current officers and key employees (Form 990 Part IX, line 5) against $3.4B in revenue. The ratio is well within the bands third-party charity raters consider reasonable at this scale. Dana Farber Cancer Institute is in the Medical Research category — public-affairs, civic, and research-policy organizations. The sector includes think tanks, advocacy organizations, and policy-research nonprofits.